Yayın:
Assessment of quality of life in ipf patients: A multicenter observational study

dc.contributor.authorUzer, Fatih
dc.contributor.authorÇilli, Aykut
dc.contributor.authorHanta, Ismail
dc.contributor.authorSevinç, Can
dc.contributor.authorLeblebici, Asım
dc.contributor.authorYılmaz, Gözde
dc.contributor.authorKamel, İbrahim
dc.contributor.buuauthorCOŞKUN, NECMİYE FUNDA
dc.contributor.buuauthorYAZICI, GAMZE
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentGöğüs Hastalıkları Ana Bilim Dalı.
dc.contributor.researcheridAAI-3169-2021
dc.date.accessioned2025-02-17T05:47:29Z
dc.date.available2025-02-17T05:47:29Z
dc.date.issued2024-01-01
dc.description.abstractAim: This study aimed to examine how dyspnea, cough, sleep disruption, anxiety, depression, and physiological factors affect the quality of life in newly diagnosed, untreated IPF patients. Methods: This study is a multicenter observational study. Patients not receiving antifibrotic treatment were included. To assess patients' and physiology (GAP) score, and Pittsburgh Sleep Quality Index (PSQI) were administered. Results: Among 88 patients (mean age: 67.6 +/- 8.5 years), 81.9% were diagnosed with IPF through HRCT, 14.8% through surgery, and 3.4% via cryobiopsy. The average disease duration was 2.2 +/- 2.9 years. Over 50% experienced moderate to severe depression, and 40% had moderate to severe anxiety. In the IPF group, 13.6% had possible usual interstitial pneumonia (UIP), and 81.8% had definite UIP pattern. No significant differences were found between UIP groups in various scores. Anxiety and depression correlated negatively with respiratory function and positively with MMRC score and BDI. Sleep quality scores had similar correlations. Patients with good sleep quality had better respiratory parameters (p=0.013), lower MMRC (p=0.004), BDI (p=0.026), and CPI (p=0.047). Conclusion: A notable number of IPF patients in follow-up show symptoms of anxiety and depression. Moreover, declining respiratory function not only diminishes sleep quality but also elevates dyspnea scores.
dc.identifier.doi10.36141/svdld.v41i3.15805
dc.identifier.issn1124-0490
dc.identifier.issue3
dc.identifier.scopus2-s2.0-85215439709
dc.identifier.urihttps://doi.org/10.36141/svdld.v41i3.15805
dc.identifier.urihttps://hdl.handle.net/11452/50454
dc.identifier.volume41
dc.identifier.wos001325502800001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherMattioli 1885
dc.relation.journalSarcoidosis Vasculitis And Diffuse Lung Diseases
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectIdiopathic pulmonary-fibrosis
dc.subjectValidation
dc.subjectIndex
dc.subjectIpf
dc.subjectMood disorders
dc.subjectQuality of life
dc.subjectSleep disturbance
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectRespiratory system
dc.subjectRespiratory system
dc.titleAssessment of quality of life in ipf patients: A multicenter observational study
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Göğüs Hastalıkları Ana Bilim Dalı.
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication061153e8-bbd9-4c2a-97f6-dc51171a1143
relation.isAuthorOfPublicationaaa08d5d-15fa-4418-979e-08025b400fd0
relation.isAuthorOfPublication09f93f96-5325-45e7-bf28-4ad8e8c46d6d
relation.isAuthorOfPublication.latestForDiscovery061153e8-bbd9-4c2a-97f6-dc51171a1143

Dosyalar